Pharma Focus Asia

Cygenica Introduced Novel Drug Conjugate in Glioblastoma Multiforme Treatment

CyGenica has introduced novel drug conjugate for the treatment of Glioblastoma Multiforme (GBM). 

GBM is a particularly challenging form of brain cancer, and innovative approaches to its treatment are sorely needed.

GEENIE offers a promising avenue for delivering therapeutics, including nucleotide-based treatments like antisense oligonucleotides, SiRNAs, and genome editing therapeutics.

This versatile platform has the potential to not only address GBM but also various other cancers and rare diseases, which is a testament to its versatility and potential impact in the field of medicine.

The integration of GEENIE platform to the treatment of GBM represents a pivotal moment in their journey and a significant step forward in the development of innovative therapies for challenging diseases, bringing hope to patients battling cancer and rare conditions.

U.S. Food and Drug Administration has granted orphan drug designation for their revolutionary drug conjugate for the treatment of GBM.


Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Thermo Fisher Scientific - Rapid Mycoplasma TestingAsia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024The Drug Safety Symposium 2024Medlab Middle East 2024ISPE Singapore Affiliate Conference & Exhibition 2024